In EGFR‐mutant NSCLC, analyses from EURTAC and LUX‐Lung 3 failed to demonstrate a consistent association between DpR and long‐term survival [14], whereas immunotherapy trials such as OAK and POPLAR reported that ETS ≥ 10% at week 6 strongly correlated with improved OS and PFS in patients treated with atezolizumab [12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.